Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer

详细信息	查看全文 | 推荐本文 |

• 作者：Hiroshi Miyata^a ; ^{hmiyata@gesrug.med.osaka-u.ac.jp} ; Masahiko Yano^b ; Takushi Yasuda^c ; Rie Hamano^a ; Makoto Yamasaki^a ; Eihou Hou^c ; Masaaki Motoori^b ; Osamu Shiraishi^c ; Koji Tanaka^b ; Masaki Mori^a ; Yuichiro Doki^a
• 关键词：Esophageal cancer ; Chemotherapy ; Enteral nutrition ; Toxicity ; Adverse effect ; Neoadjuvant
• 刊名：Clinical Nutrition
• 出版年：2012
• 期刊代码：52_02615614
• 类别：med
• 出版时间：June, 2012
• 卷：31
• 期：3
• 页码：330-336
• 文件大小：349 K

摘要

| Figures/TablesFigures/Tables | ReferencesReferences

Summary

Background & aims

Enteral nutrition (EN) is provided for patients with cancer. However, Little is known about the clinical efficacy of EN support during chemotherapy in patients with cancer.

Methods

Ninety-one patients who received neoadjuvant chemotherapy (5-fluorouracil, cisplatin and adriamycin) for esophageal cancer were enrolled to receive either EN (n聽=聽47) or PN (n聽=聽44) at random. The primary endpoint was the incidence of chemotherapy-related toxicities during chemotherapy.

Results

Total and dietary intake calories during chemotherapy were equal in the two groups. There were no significant differences in serum albumin level and body weight change after chemotherapy between the two groups. There was no significant difference in tumor response to chemotherapy between the two groups (EN: 51%, PN: 55%, p聽=聽0.886). Leukopenia and neutropenia of grade 3 or 4, defined according to the Common Toxicities Criteria of the National Cancer Institute, were significantly less frequent in the EN group than PN group (leukopenia: 17%vs 41%, p聽=聽0.011, neutropenia: 36%vs 66%, p聽=聽0.005). Lymphopenia and thrombocytopenia tended to be less frequent in the EN group, albeit insignificantly.

Conclusions

Compared with PN support, EN support during neoadjuvant chemotherapy reduced the incidence of chemotherapy-related hematological toxicities in patients with esophageal cancers.

The clinical trial registration number

UMIN000004483